GLP-1 RAs and Suicidality: Weighing Out The Risks
Galter Health Sciences Library, Northwestern University · 03.06.2025
DOI: 10.18131/gxeff-sas84 ↗Kurz gefasst
Fachartikel in der Zeitschrift Galter Health Sciences Library, Northwestern University, erschienen am 03.06.2025. Verfasst von Riley Kishman und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This literature analysis reviews four articles published in 2024 about Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and a potential risk of suicide. GLP-1 RAs are at the forefront of medical therapy for patients with obesity and type 2 diabetes mellitus. They are relatively new to the market, and have increased in popularity over the last few years because of their positive effects of glucose control and weight loss. In mid 2023, reports of suicidal behavior with use of GLP-1 RAs prompted the European Medicines Agency (EMA) to investigate further. Determining adverse effects of GLP-1 RAs is crucial because these medications are going to be around for the foreseeable future and continue to gain popularity. Suicide is one of the leading causes of death in the United States, and if there is an association of suicidality with GLP-1 RA use, it is important for clinicians to know when they are prescribing these medications.
Schlagwörter
Zitieren
APA
Kishman, R., & Fotis, M. (2025). GLP-1 RAs and Suicidality: Weighing Out The Risks. Galter Health Sciences Library, Northwestern University. https://doi.org/10.18131/gxeff-sas84
Vancouver
Kishman R, Fotis M. GLP-1 RAs and Suicidality: Weighing Out The Risks. Galter Health Sciences Library, Northwestern University. 2025. doi:10.18131/gxeff-sas84
BibTeX
@article{Kishman2025,
author = {Kishman, Riley and Fotis, Michael},
title = {GLP-1 RAs and Suicidality: Weighing Out The Risks},
journal = {Galter Health Sciences Library, Northwestern University},
year = {2025},
doi = {10.18131/gxeff-sas84}
}
EUVIMED